The occurrence of upper-extremity arterial disease is less common than that of the lower extremities. Nevertheless, exercise-induced symptoms, when present, can significantly affect functional capacity and limit quality of life. We report a case of exertional right upper-extremity pain and severe right axillary artery disease that was revascularized using an off-label drug-coated balloon technology with resolution of symptoms.
C linical manifestations of upper-extremity arterial disease tend to be distinct from those of lower-extremity disease, given the abundance of collateral circulation (1, 2) . Th e main focus in managing upper-extremity arterial disease is treatment of preexisting cardiovascular risk factors with aggressive medical therapy and lifestyle modifi cation. When refractory symptoms ensue, surgical or percutaneous revascularization should be considered. Surgery with bypass grafts has been associated with improved patency compared to endovascular therapy, but with comparable complication rates (3) . When endovascular therapy is considered, the preferred method remains controversial (4, 5) . We present a patient with symptoms of right upper-extremity claudication and likely obstructive atherosclerotic disease of the axillary artery who underwent successful revascularization using drug-coated balloon angioplasty with subsequent resolution of symptoms.
CASE REPORT
A 66-year-old woman presented with right arm claudication. She had a prior history of hypertension, hyperlipidemia, pulmonary sarcoidosis, rheumatic heart disease, atrial fi brillation, and a permanent pacemaker for tachy-brady syndrome. She had extensive atherosclerotic disease with known nonobstructive coronary and carotid artery disease and previous percutaneous revascularization for peripheral arterial disease. Th e patient had been maintained on aspirin and clopidogrel.
She presented with progressive symptoms of right arm discomfort, aggravated by exercise and heavy-object lifting. A 6Fr 90 cm Cook sheath was advanced via the left common femoral artery into the right brachiocephalic trunk for endovascular intervention using standard sheath delivery techniques. Unfractionated heparin with a goal partial thromboplastin time of 250 to 300 seconds was given. Th e lesions in the axillary artery were crossed using a 0.018˝ gold-tip Glidewire (Terumo Medical Corp., Somerset, NJ). Th e 0.018˝ glidewire was exchanged for a supportive 0.035˝ SupraCore wire ( Abbott, and showed multifocal obstructive atherosclerotic lesions of the axillary arteries bilaterally. Serologic studies had been negative for an underlying infl ammatory and/or autoimmune process with the exception of a mildly elevated erythrocyte sedimentation rate. Th e patient underwent upper-extremity angiography, confi rming the sonographic and CT angiography fi ndings (Figure 1a) . Given optimal medical therapy and refractory right arm claudication, the patient opted for endovascular therapy. Chicago, IL). Th e right axillary artery lesions were subsequently predilated with a 4.0 mm × 40 mm Armada balloon (Abbott, Chicago, IL), followed by drug-coated balloon angioplasty with an IN.PACT Admiral 4.0 mm × 120 mm balloon (Medtronic, Minneapolis, MN). Postintervention angiography revealed excellent luminal expansion without evidence of fl ow-limiting dissections (Figure 1b) . Postprocedurally, the patient reported resolution of her right upper-extremity symptoms, and the blood pressure diff erential had resolved. At 6-and 12-month follow-up, she remained asymptomatic, with 2+ right brachial, radial, and ulnar pulses.
DISCUSSION
Given the rarity of atherosclerotic axillary artery disease, most data on short-and long-term outcomes following percutaneous transluminal angioplasty (PTA) and/or stenting of focal upper-extremity atherosclerotic disease are extrapolated from subclavian artery revascularization (6) ( Table 1 ). In a retrospective study evaluating outcomes in 274 patients treated with either a conservative (n = 165) or invasive (n = 109) approach for subclavian artery atherosclerotic disease with a median follow-up of 42 months, patients treated with PTA had a 60% risk reduction for the development of a hemodynamically signifi cant stenosis (P < 0.01), defi ned as an upperextremity blood pressure diff erential of ≥20 mm Hg compared with conservative treatment (7) .
Improvements in stent technology, coupled with widespread use, paved the way for studies evaluating the effi cacy of stenting in upper-extremity vessels. An initial study by Sueoka et al (8) evaluated the effi cacy of balloon-expandable stents in treating proximal subclavian artery stenosis causing subclavian steal syndrome after failure of an initial approach with PTA, with a procedural success rate of 100%. Subsequent studies by Rodriguez-Lopez et al (9) and Henry et al (10) demonstrated good short-and mid-term patency rates, with similar longterm patency rates compared with PTA. A recently published meta-analysis of 35 noncomparative studies with 1726 patients examining PTA and stenting in subclavian arterial occlusive disease found that technical success rates were higher in stented patients, without a statistical diff erence in rates of symptom resolution and long-term primary patency rates (6) . We report the fi rst case of symptomatic axillary artery disease successfully treated with off -label drug-coated balloon angioplasty and resolution of symptoms postprocedurally.
